411 related articles for article (PubMed ID: 19146203)
1. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial.
Costantino D; Guaraldi C
Eur Rev Med Pharmacol Sci; 2008; 12(6):411-6. PubMed ID: 19146203
[TBL] [Abstract][Full Text] [Related]
2. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy.
Morali G; Polatti F; Metelitsa EN; Mascarucci P; Magnani P; Marrè GB
Arzneimittelforschung; 2006; 56(3):230-8. PubMed ID: 16618016
[TBL] [Abstract][Full Text] [Related]
3. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause.
Le Donne M; Caruso C; Mancuso A; Costa G; Iemmo R; Pizzimenti G; Cavallari V
Arch Gynecol Obstet; 2011 Jun; 283(6):1319-23. PubMed ID: 20577750
[TBL] [Abstract][Full Text] [Related]
4. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets.
Panay N; Maamari R
Menopause Int; 2012 Mar; 18(1):15-9. PubMed ID: 22393176
[TBL] [Abstract][Full Text] [Related]
5. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
[TBL] [Abstract][Full Text] [Related]
6. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
Simon JA; Reape KZ; Wininger S; Hait H
Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
[TBL] [Abstract][Full Text] [Related]
7. Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort.
Grimaldi EF; Restaino S; Inglese S; Foltran L; Sorz A; Di Lorenzo G; Guaschino S
Minerva Ginecol; 2012 Aug; 64(4):321-9. PubMed ID: 22728576
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL
Menopause; 2009; 16(5):978-83. PubMed ID: 19390463
[TBL] [Abstract][Full Text] [Related]
9. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
Al-Baghdadi O; Ewies AA
Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of local estrogen therapy for urogenital atrophy.
Archer DF
Menopause; 2010; 17(1):194-203. PubMed ID: 19602990
[TBL] [Abstract][Full Text] [Related]
11. Management of post-menopausal vaginal atrophy and atrophic vaginitis.
Castelo-Branco C; Cancelo MJ; Villero J; Nohales F; Juliá MD
Maturitas; 2005 Nov; 52 Suppl 1():S46-52. PubMed ID: 16139449
[TBL] [Abstract][Full Text] [Related]
12. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
[TBL] [Abstract][Full Text] [Related]
13. Investigating the effect of vitamin D vaginal suppository on sexual function among postmenopausal women: study protocol for a randomized controlled trial.
Sarebani Z; Alimoradi Z; Aali E; Mirzadeh M; Chegini V; Abbaspour M; Griffiths MD
BMC Womens Health; 2020 Feb; 20(1):27. PubMed ID: 32070323
[TBL] [Abstract][Full Text] [Related]
14. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
Stute P
Arch Gynecol Obstet; 2013 Dec; 288(6):1199-201. PubMed ID: 24178484
[TBL] [Abstract][Full Text] [Related]
15. The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial.
Manonai J; Songchitsomboon S; Chanda K; Hong JH; Komindr S
Maturitas; 2006 May; 54(2):135-40. PubMed ID: 16297576
[TBL] [Abstract][Full Text] [Related]
16. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.
Crandall C
J Womens Health (Larchmt); 2002 Dec; 11(10):857-77. PubMed ID: 12626086
[TBL] [Abstract][Full Text] [Related]
17. [Topical hormonal treatment and urogenital atrophy].
Sitruk-Ware R; Thomas JL
Praxis (Bern 1994); 1997 Aug; 86(33):1245-8. PubMed ID: 9381009
[TBL] [Abstract][Full Text] [Related]
18. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women.
Levine KB; Williams RE; Hartmann KE
Menopause; 2008; 15(4 Pt 1):661-6. PubMed ID: 18698279
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
Cano A; Estévez J; Usandizaga R; Gallo JL; Guinot M; Delgado JL; Castellanos E; Moral E; Nieto C; del Prado JM; Ferrer J
Menopause; 2012 Oct; 19(10):1130-9. PubMed ID: 22914208
[TBL] [Abstract][Full Text] [Related]
20. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
